Our study aimed at assessing the prognostic value of baseline endogenous EPO for short- and mid-term survival in patients with severe aortic valve stenosis undergoing TAVR, and whether this is related to or independent from the prognostic impact of anemia and renal function, in patients with preserved renal function. This evidence concerns the gene EPO and anemia.